logo
Share SHARE
FONT-SIZE Plus   Neg

AstraZeneca Advances MedImmune's Benralizumab To Phase III In Severe Asthma

AstraZeneca (AZN.L,AZN) said it has begun the Phase III Windward programme for benralizumab, a potential treatment for severe uncontrolled asthma developed by MedImmune, the company's global biologics research and development arm. The aim of CALIMA, the first trial in the Windward programme, is to determine whether benralizumab reduces the number of exacerbations in patients with severe asthma that remains uncontrolled, despite receiving high doses of inhaled corticosteroids combined with a second controller like long-acting beta agonist.

Benralizumab is a monoclonal antibody binding to the interleukin-5 receptor, that depletes eosinophils, a type of white blood cell, which play a critical role in the cause and severity of asthma and asthma exacerbations. Emerging evidence demonstrates that for patients with elevated eosinophil counts, treatment with an IL-5 inhibitor in addition to guideline-based strategies may increase their asthma control and decrease the frequency of asthma attacks.

The CALIMA trial would evaluate the safety and effectiveness of benralizumab in actively reducing exacerbations in patients with uncontrolled asthma, and assess the benralizumab effect on lung function, asthma symptoms and other asthma control measures, as well as emergency room and hospitalisation rates due to asthma.

The efficacy and safety data from this trial supported the progression of benralizumab into our Phase III programme. These results are likely to be shared at a scientific conference in the first half of 2014. Benralizumab is in-licensed from BioWa, Inc., a subsidiary of Kyowa Hakko Kirin Co., Ltd.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Federal Communications Commission or FCC will not take any action against CBS Corp.'s "Late Show with Stephen Colbert" despite receiving thousands of complaints about the talk show comedian's controversial joke about President Donald Trump. The U.S. government filed a civil lawsuit on Tuesday against Fiat Chrysler Automobiles, accusing the automaker of installing software in more than 100,000 diesel vehicles to cheat emission controls. The lawsuit alleges that Fiat Chrysler equipped nearly 104,000 light duty diesel vehicles containing 3.0 liter EcoDiesel engines with software functions that were not disclosed to regulators. A college degree is a necessity for a rewarding, well-paying job with possibility for career advancement and also for entry into most professional careers. On average, college graduates earn much more than high school graduates throughout their lifetime. In addition to the earnings potential, students...
comments powered by Disqus
Follow RTT